Nipent (Pentostatin)

Pentostatin, the active ingredient in Nipent, is a purine analog antineoplastic agent presented as an intravenous formulation for use in adult patients. It is employed in the treatment of specific hematologic malignancies, notably hairy cell leukemia and chronic lymphocytic leukemia, where it targets malignant lymphocytes to inhibit disease progression.

GNH USA supplies Nipent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with a focus on quality assurance and regulatory compliance across EU and global markets.

Pentostatin is used in hematologic oncology to target malignant lymphoid cells across several disease categories, helping to improve patient outcomes. - Hairy cell leukemia: induces durable remission by inhibiting adenosine deaminase, leading to accumulation of toxic nucleotides and apoptosis of malignant B‑cells. - Chronic lymphocytic leukemia: reduces abnormal lymphocyte proliferation and disease burden, improving blood counts and clinical symptoms in affected patients. - Other lymphoid malignancies: provides disease control in various non‑Hodgkin lymphomas and related disorders through targeted inhibition of DNA synthesis in lymphoid cells.

Pentostatin may cause a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Nausea: mild to moderate nausea often occurring during infusion. - Fatigue: generalized tiredness and reduced energy levels. - Fever: low‑grade temperature elevations without infection. - Myelosuppression: decreased blood cell counts, especially neutrophils. - Infections: increased susceptibility to bacterial or viral infections. - Alopecia: temporary hair thinning or loss. Serious or Rare Side Effects: - Severe neutropenia: profound drop in neutrophils leading to high infection risk. - Opportunistic infections: reactivation of latent viruses such as herpes or CMV. - Pulmonary toxicity: interstitial pneumonitis or respiratory distress. - Anaphylaxis: acute hypersensitivity reaction requiring immediate medical attention.

When using Pentostatin, careful monitoring and specific precautions are essential to minimize risks. - Monitor blood counts: perform complete blood count before each dose and regularly during therapy. - Assess infection risk: screen for active infections and provide prophylactic antibiotics when indicated. - Evaluate renal function: adjust therapy if significant renal impairment is present. - Avoid concurrent myelosuppressive agents: limit use with other chemotherapy that suppresses bone marrow. - Pregnancy and lactation: contraindicated in pregnant or breastfeeding women due to potential fetal toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Pentostatin can interact with other medicines, altering its efficacy or toxicity profile. Major Interactions (Avoid): - Concurrent antimetabolites (e.g., cytarabine, fludarabine): may cause additive myelosuppression. - Live vaccines: increased risk of severe infection due to immunosuppression. - High‑dose radiation therapy: heightened tissue toxicity when combined. - Allopurinol: may exacerbate hematologic toxicity. Moderate Interactions (Monitor Closely): - Azathioprine: potential for enhanced bone marrow suppression; monitor blood counts. - Antifungal agents (e.g., fluconazole): may increase Pentostatin plasma levels; adjust dose if needed. - NSAIDs: may affect renal function, requiring monitoring in patients with compromised kidneys.